RHEACELL
LIVE

Serial Number

79229551

Owner

RHEACELL GmbH & Co. KG

Attorney

Claudia W. Stangle

Filing Date

Feb 5, 2018

Add to watchlist:

No watchlists yet
View on USPTO

RHEACELL Trademark

Serial Number: 79229551 • Registration: 5694020

RHEACELL is a trademark filed by RHEACELL GmbH & Co. KG on February 5, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

RHEACELL GmbH & Co. KG (9 trademarks)

Im Neuenheimerfeld 517

Entity Type: 28

Trademark Details

Filing Date

February 5, 2018

Registration Date

March 12, 2019

Published for Opposition

December 25, 2018

Goods & Services

Pharmaceutical [ and veterinary ] preparations for treatment of skin diseases; pharmaceutical [ and veterinary ] preparations for the treatment of vertigo; pharmaceutical [ and veterinary ] preparations for treatment of nausea; [ pharmaceutical and veterinary preparations for treatment of vomiting; pharmaceutical and veterinary preparations for treatment of migraine; ] pharmaceutical [ and veterinary ] preparations for treatment of disease and disorders of the respiratory system, the gastrointestinal system, the endocrine system, the cardiovascular system, the nervous system, the musculoskeletal system, [ the urinary system, ] the integumentary system [, and the reproductive system ]; pharmaceutical [ and veterinary ] preparations for treatment of blood diseases and disorders; pharmaceutical [ and veterinary ] preparations, namely, antibiotics, immune suppressants, anti-inflammatory pharmaceuticals; pharmaceutical [ and veterinary ] preparations for wound healing; pharmaceutical [and veterinary preparations for anti-aging, namely, stem cells for medical and aesthetic purposes, [ fibroblasts for medical and aesthetic purposes, ] surgical tissue implants obtained from stem cells [ , surgical tissue implants obtained from fibroblasts ]

Medical services

Scientific and technological services, namely medical and scientific research services in the fields of regenerative medicine and tissue engineering, scientific research, testing and analysis services in the field of regenerative medicine and tissue engineering, consulting services relating to scientific research in the fields of regenerative medicine and tissue engineering, providing information on medical and scientific research on pharmaceutical products, providing information in the form of expert reports relating to scientific research in the fields of regenerative medicine and tissue engineering; Industrial analysis, namely chemical analysis; research services, namely laboratory research services relating to pharmaceuticals, medical, biomedical and stem cell research in the field of regenerative medicine and tissue engineering, scientific and medical research and development for medical purposes in the field of regenerative medicine and tissue engineering, research and development services relating to new products for others, research in the field of biotechnology, research in the field of gene therapy, research and development in the field of immunology, research and development in the field of antibodies, research and development in the field of antibody technology, research and development in the field of bacteriology, research and development in the field of gene expression systems, research and development in the field of vaccines, pharmaceutical research and development services, research and development services in the field of biotechnology

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
May 14, 2026 NREP
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Mar 7, 2026 INPR
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Jul 7, 2025 NA75
REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Jul 7, 2025 C75A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Jun 30, 2025 APRE
TEAS SECTION 71 & 15 RECEIVED
Mar 27, 2025 ES75
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Mar 12, 2024 REM3
INTERNATIONAL REGISTRATION RENEWED
Jan 4, 2024 RNWL
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 19, 2019 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 1, 2019 FICS
FINAL DISPOSITION PROCESSED
Jul 1, 2019 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 12, 2019 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 12, 2019 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 25, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 25, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 5, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 13, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 24, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 23, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Oct 23, 2018 ERFR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 19, 2018 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 19, 2018 REAP
FINAL REFUSAL MAILED
Sep 10, 2018 CNFR
FINAL REFUSAL WRITTEN
Sep 10, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Aug 21, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Aug 21, 2018 CRFA
ASSIGNED TO LIE
Aug 21, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Aug 1, 2018 TROA
REFUSAL PROCESSED BY IB
Jun 8, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 23, 2018 RFCS
REFUSAL PROCESSED BY MPU
May 23, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 19, 2018 RFCR
NON-FINAL ACTION WRITTEN
May 18, 2018 CNRT
ASSIGNED TO EXAMINER
May 17, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
Apr 4, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 31, 2018 NWOS
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Mar 29, 2018 SDRC